Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., has a current stock price of 56.75 yuan, with a rolling PE ratio of 31.94, marking a new low in 94 days, and a total market capitalization of 13.199 billion yuan [1] Company Summary - Haohai Biological specializes in the research, production, and sales of medical devices and pharmaceuticals, with key products including ophthalmic viscoelastic devices, artificial lenses, optical materials, hyaluronic acid, and medical chitosan [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.312 million yuan, down 7.41%, with a gross profit margin of 69.52% [1] Industry Summary - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning Haohai Biological at 61st place within the industry [2] - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Haohai Biological Technology Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1][2] - As of June 3, the company's stock closed at 53.32 yuan, with a rolling PE ratio of 30.09, marking a new low in 28 days, and a total market value of 12.434 billion yuan [1] - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, positioning Haohai Biological at the 66th rank within the industry [1][2] Group 2 - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 619 million yuan, reflecting a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41% year-on-year, with a gross margin of 69.52% [1] - As of the Q1 2025 report, three institutions hold shares in Haohai Biological, with a total of 2.4635 million shares valued at 146 million yuan [1]

昊海生科展馆视觉中国供图 羊城晚报记者 汪海晏 近日，上海昊海生物科技股份有限公司（以下简称"昊海生科"）发布公告称，公司控股股东、实际控制 人之一蒋伟因涉嫌内幕交易，被中国证监会立案调查，但此事与公司股票无关。 不过，尽管蒋伟本人并不在上市公司担任具体职务，也不参与公司日常经营管理，公司日常运作由以侯 永泰、吴剑英为核心的专业管理团队负责。但作为创始人与实控人，蒋伟对公司发展方向有着深远影 响。 早期，昊海有限公司通过引入上海华源生命科学研究开发有限公司完成首次增资，切入医用透明质酸钠 （即玻尿酸）领域。此后，昊海生科开启频繁的并购扩张之路，在眼科领域，2015-2021年间接连收购 昊海生科在公告中特别强调："本次事项系对蒋伟先生个人的调查，其不参与公司日常经营管理，该事 项不会对公司日常经营活动产生重大影响。"尽管公司极力撇清与该事件的关系，但资本市场迅速作出 反应。截至5月9日收盘，A股昊海生科股价收报52元，下跌0.5%，总市值121亿元；港股股价则下跌 1.69%。 5月11日，羊城晚报记者就该事件对公司带来的影响、公司目前的应对措施、未来战略规划等相关问题 采访昊海生科，截至发稿未收到回复。 实 ...

Core Viewpoint - Haohai Biological Technology's performance in 2024 shows stagnation in revenue and profit growth, primarily due to the declining market for hyaluronic acid and the impact of national procurement policies on its ophthalmology and orthopedics segments [3][5][16]. Revenue and Profit Summary - In 2024, Haohai Biological Technology achieved revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, up 1.04% year-on-year [3]. - The medical beauty and wound care products contributed 1.195 billion yuan to revenue, accounting for 44.30% of total revenue, with a growth of 13.08% year-on-year [8]. Business Segment Analysis - The medical beauty segment, which includes hyaluronic acid, epidermal growth factor, and RF and laser equipment, generated 742 million yuan from hyaluronic acid, representing 62.05% of the medical beauty segment [8]. - The ophthalmology segment generated 858 million yuan, accounting for 31.79% of total revenue, showing a decline of 7.60% year-on-year [16]. Market Dynamics - The hyaluronic acid market is experiencing increased competition and a decline in growth, with high-end products facing challenges from competitors like Juvederm and Restylane [14]. - The rise of alternative products, such as hydroxyapatite, is reshaping the aesthetic market, as consumers are becoming more cautious about hyaluronic acid fillers [14]. Regulatory Impact - The regulatory changes in 2022 have affected the sales of RF and laser devices, with significant reductions in revenue from home-use and aesthetic-grade products starting in 2023 [15]. Product Performance - The revenue from cataract surgeries in 2024 was 420 million yuan, down 15.33% year-on-year, with artificial lenses and ophthalmic viscoelastic devices also showing declines [20].